

#### Next generation therapies to end TB

#### **BUILDING BLOCKS OF ERADICATION**



Short, effective,

# UNIVERSAL REGIMEN

for all forms of Active TB





Short, effective,

# UNIVERSAL THERAPY

for Latent TB

# TB Alliance | Drug development pipeline\*

**DISCOVERY EARLY DEVELOPMENT** LATE DEVELOPMENT **LEAD** PRECLINICAL PHASE 1-PHASE 2 PHASE 3 LEAD MARKETED **IDENTIFICATION OPTIMIZATION DEVELOPMENT PRODUCTS** Completed Nixtb **Malate Synthetase** BPaMZ /SEM Anti-TB Natural **Long-Acting Injectables TBAJ-587** BPaL **OPTIMIZED PEDIATRIC** /Diarylquinoline bedaquiline + Inhibitors **Products** (LAIs) UoSA **FORMULATIONS** pretomanid + ERA4TB Texas A&M Pretomanid Evotec linezolid with Macleods TBAJ-876 UNITF4TB NC009 Viatris Ethambutol TBAJ-587 MDH-1 ClpC1 Q-203 Isoniazid **TBAJ-876** Texas A&M Harvard **BPaL** Pvrazinamide **ZeNix** /Diarylquinoline **WCM** UIC **Preclinical TB Regimen** bedaquiline + Rifampicin / Isoniazid pretomanid + Development Rifampicin / Isoniazid / Q-203 ClpP1P2 Programs PknB linezolid Pyrazinamide JHU ERA4TB Schrödinger **GHDDI** Viatris ERA4TB **NCATS** X-Chem Harvard **TBDA** Qurient **PEDIATRIC** UIC **BPaMZ** SIMPLICITE **FORMULATION** bedaquiline + **PptT PAN-TB Collaboration DEVELOPMENT** Sutezolid / pretomanid + Intracellular Evotec **BMGF Pretomanid** Oxazolidinone moxiflaxacin + **Active Series** Texas A&M Viatris PAN-HM | Aurum pyrazinamide UNC Evotec PAN-TB | Gates MRI. PanACEA **WCM** GSK Janssen, Otsuka Radboud **PRETOMANID** RAD-TB | ACTG Viatris **FOR USE** Whole Cell Hit-to-Lead **MmpL3 Inhibitors IN BPaL** TBA-7371 / **Program** Pretomanid for use in BPaL AbbVie TB Practecal : DprE1 Inhibitor Innovating MDR-TB Treatment and BPaLM Regimens GSK **ERA4TB FNDR BPaL/M** Hongqi Gates MRI **RNA Polymerase** bedaquiline + ITRC pretomanid + Inhibitors Lupin Scan here TBI-223 / linezolid + Macleods Lgenia for the online moxiflaxacin Oxazolidinone Viatris UoA

IMM

RAD-TB | ACTG

MSF Amsterdam

portfolio

<sup>\*</sup>As of November 2024. This document is updated on a guarterly basis.




### TB Alliance | Portfolio partners







#### Toward the first universal regimen






#### Accelerating development and treatment pathways







#### Maximizing the impact of our pipeline



# CO-DEVELOPMENT FOR ADDITIONAL DISEASES WHEN:

- Unmet need and compelling science
- Synergistic with TB work
- Sources of incremental external funding

#### TACKLING LATENT TB



NEWER, MORE POTENT DRUGS

with properties conducive to


LAI formulation — enabling
immense treatment shortening

TRACK RECORD OF LAI SUCCESS

in other disease areas


ESTABLISHED CLINICAL TRIAL NETWORKS

experienced in conducting LTBI trials






New approaches currently in development to realize the next quantum leap in treatment shortening





# The Future of TB Treatment





#### **ONE DAY**

to treat latent TB infections



#### **ONE MONTH**

to treat active TB infections